PTK2 and neoplasm: FAK inhibitors have shown promising anti-tumor effects in clinical settings by inhibiting CAF activation, reducing collagen deposition, and further promoting the infiltration of anti-tumor immune cells, including CD8+ T cells and dendritic cells into the tumor, thereby remodeling the tumor microenvironment (TME) [30], which aligns with our in vivo flow cytometry results (Fig. 7).